Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

CHROMADEX CORPORATION

(CDXC)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
04/13/2021 04/14/2021 04/15/2021 04/16/2021 04/19/2021 Date
9.04(c) 8.68(c) 8.53(c) 8.2(c) 7.96(c) Last
758 365 907 744 461 419 823 663 1 573 461 Volume
+0.67% -3.98% -1.73% -3.87% -2.93% Change
More quotes
Financials (USD)
Sales 2021 76,4 M - -
Net income 2021 -17,7 M - -
Net Debt 2021 - - -
P/E ratio 2021 -28,9x
Yield 2021 -
Sales 2022 107 M - -
Net income 2022 -1,83 M - -
Net Debt 2022 - - -
P/E ratio 2022 -265x
Yield 2022 -
Capitalization 531 M 531 M -
Capi. / Sales 2021 6,95x
Capi. / Sales 2022 4,97x
Nbr of Employees 110
Free-Float 57,4%
More Financials
Company
Chromadex Corporation is an integrated nutraceutical company. The Company and its subsidiaries ChromaDex, Inc., ChromaDex Analytics, Inc. and Spherix Consulting, Inc. provides research and quality-control products and services to the natural products industry. The Company partners with universities and research institutions worldwide to discover, develop and create solutions to deliver the full potential of... 
More about the company
Notations Surperformance© of ChromaDex Corporation
Trading Rating : Investor Rating :
More Ratings
All news about CHROMADEX CORPORATION
04/19CHROMADEX  : Taps Fadi Karam for Marketing Chief
MT
04/19CHROMADEX  : Appoints Fadi Karam as Chief Marketing Officer
BU
03/31CHROMADEX  : in Partnership with Citrin Foundation of Singapore to Study Citrin ..
MT
03/31CHROMADEX  : and the Citrin Foundation Announce Global Research Collaboration Ex..
BU
03/24CHROMADEX  : to Present at the Lytham Partners Spring 2021 Investor Conference
BU
03/24CHROMADEX  : Files Shelf for Up to About 3.8 Million Common Shares on Behalf of ..
MT
03/18CHROMADEX  : March 2021 Investor Presentation
PU
03/18CHROMADEX  : to Present at the Zooming with LD Virtual Investor Conference
BU
03/16CHROMADEX  : HC Wainwright Adjusts Price Target on ChromaDex to $16 From $7, Mai..
MT
03/12CHROMADEX  : Oppenheimer Adjusts ChromaDex PT to $17 From $9, Maintains Outperfo..
MT
03/12CHROMADEX  : Management's Discussion and Analysis of Financial Condition and Res..
AQ
03/10CHROMADEX  : Narrows Q4 Net Loss on Rising Revenue, Sees Steady Sales Growth in ..
MT
03/10CHROMADEX  : Q4 2020 Earnings Presentation
PU
03/10CHROMADEX CORP.  : Results of Operations and Financial Condition, Regulation FD ..
AQ
03/10CHROMADEX  : Earnings Flash (CDXC) CHROMADEX CORPORATION Reports Q4 Revenue $15...
MT
More news
News in other languages on CHROMADEX CORPORATION

- No features available -

More news
Analyst Recommendations on CHROMADEX CORPORATION
More recommendations
Chart CHROMADEX CORPORATION
Duration : Period :
ChromaDex Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CHROMADEX CORPORATION
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Average target price 16,67 $
Last Close Price 7,96 $
Spread / Highest target 151%
Spread / Average Target 109%
Spread / Lowest Target 50,8%
EPS Revisions
Managers and Directors
NameTitle
Robert N. Fried Chief Executive Officer & Director
Kevin M. Farr Chief Financial Officer
Frank L. Jaksch Executive Chairman
Aron Erickson Vice President-Research & Development
Ben Shichman Chief Technical Officer
Sector and Competitors
1st jan.Capitalization (M$)
CHROMADEX CORPORATION65.83%531
MODERNA, INC.63.50%68 414
LONZA GROUP AG-1.83%45 120
IQVIA HOLDINGS INC.20.68%41 337
CELLTRION, INC.-13.79%37 693
SEAGEN INC.-17.77%26 380